Impact ledger
AbbVie Inc. (ABBV)
16 events mapped to this ticker since 2026-06-12.
Assumption changes
| Date | Assumption | Direction | Magnitude | Conf. |
|---|---|---|---|---|
| 2026-06-30 | revenue | Bullish | — | 0.85 |
| 2026-06-30 | revenue | Bullish | — | 0.85 |
| 2026-06-30 | revenue | Bullish | — | 0.85 |
| 2026-06-30 | revenue | Bullish | — | 0.80 |
| 2026-06-30 | revenue | Bullish | — | 0.80 |
| 2026-06-30 | revenue | Bullish | — | 0.80 |
| 2026-06-30 | revenue | Bullish | — | 0.80 |
| 2026-06-29 | revenue | Bullish | — | 0.85 |
| 2026-06-29 | revenue | Bullish | — | 0.80 |
| 2026-06-29 | revenue | Bullish | — | 0.85 |
| 2026-06-24 | margin | Bearish | — | 0.90 |
| 2026-06-24 | margin | Bearish | — | 0.90 |
| 2026-06-23 | margin | Bearish | — | 0.85 |
| 2026-06-23 | share_count | Bullish | — | 0.80 |
| 2026-06-23 | margin | Bearish | — | 0.85 |
| 2026-06-22 | share_count | Bullish | — | 0.80 |
| 2026-06-22 | share_count | Bullish | — | 0.70 |
| 2026-06-22 | net_debt | Bullish | — | 0.70 |
| 2026-06-22 | revenue | Bullish | — | 0.70 |
Event impact log
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-07-14 | Event | Acquisition cost and integration risk. Potential for dilution if financed with equity, or increased debt if financed with debt. Strategic benefits are longer term. | Bearish | 1-3m | 0.60 |
| 2026-06-30 | Event | Slower-than-expected revenue erosion for Humira due to patient re-switching from biosimilars, potentially leading to higher-than-forecasted sales. | Bullish | 1-3m | 0.70 |
| 2026-06-29 | Event | Outflow of cash for milestone payment; continued investment in pipeline asset with potential future returns. | watch | 1-3m | 0.10 |
| 2026-06-29 | Event | Payment represents an expense, but also progress on a pipeline asset. The financial impact is likely negligible relative to AbbVie's scale. | watch | 1-3m | 0.20 |
| 2026-06-23 | Event | Strategic acquisition to diversify immunology pipeline and mitigate Humira patent expiry impact. Potential for long-term revenue growth offset by acquisition costs and integration risks. | mixed | 1-5y | 0.60 |
| 2026-06-23 | Event | Strategic acquisition to diversify and strengthen immunology pipeline post-Humira, potentially offsetting future revenue declines but incurring significant acquisition costs. | mixed | 1-5y | 0.60 |
| 2026-06-23 | Event | Acquisition premium, near-term earnings dilution, increased debt/financing costs, potential integration risks. | Bearish | 1-3m | 0.70 |
| 2026-06-23 | Event | Strategic acquisition to bolster immunology pipeline, offset Humira LOE, but with significant cash outlay and potential integration risks. Law firm investigations could add minor legal costs/distraction. | mixed | 3-12m | 0.70 |
| 2026-06-23 | Event | Strategic acquisition to bolster immunology pipeline; potential for increased R&D costs and integration risks offset by future revenue growth. | mixed | 1-5y | 0.60 |
| 2026-06-22 | Event | Indirect competitive pressure in the broader neuroscience and psychiatric market. AbbVie has a presence in neurological disorders. | watch | 3-12m | 0.10 |
| 2026-06-22 | Event | Strategic acquisition to enhance immunology pipeline and mitigate future revenue erosion from patent expirations. Integration costs and potential dilution from financing could be short-term headwinds. | mixed | 1-5y | 0.70 |
| 2026-06-22 | Event | Potential competitive pressure in the immunology and inflammatory disease market. AbbVie has a strong presence in this therapeutic area with drugs like Humira and Skyrizi, which could be impacted by new entrants. | watch | 3-12m | 0.40 |
| 2026-06-22 | Event | Acquisition of late-stage immunology assets, potential for future revenue growth offset by acquisition cost and integration risks. | mixed | 1-5y | 0.70 |
| 2026-06-15 | Event | Indirect competitive pressure in the inflammatory bowel disease (IBD) market, as SPY002 could become a significant competitor to existing or pipeline IBD treatments, potentially impacting sales of established drugs. | watch | 1-3m | 0.30 |
| 2026-06-15 | Event | Potential future competition for venetoclax (Venclexta) in AML, particularly if tuspetinib progresses to market as a combination therapy. | watch | 1-5y | 0.30 |
| 2026-06-12 | Event | Successful diversification and strong clinical data in oncology, reducing reliance on Humira and supporting future revenue growth. | Bullish | 1-5y | 0.80 |
This ledger is regenerated from Market Ontology's public event pipeline. For live alerts on new assumption changes for ABBV, start a trial or view the ABBV entity page.